Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360256 · ClinicalTrials.gov registry record
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants
A clinical trial, sponsored by Augusta University.
- Completed
- Registry status
- 46
- Enrollment target
NCT00360256: Completed study, sponsored by Augusta University.
NCT00360256 is a clinical trial that has completed, run by Augusta University. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00360256 has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- 46 participants
- Enrollment target
Study Summary
The objective of this pilot study is to determine the genetic polymorphism rate of CYP450 2D6 and 2C19 metabolic enzymes in patients with significant adverse effects from antidepressants, compared to a population of patients who had no significant adverse effects from antidepressants metabolized by CYP2D6 and 2C19. The hypothesis for the proposed research is that the rate of 2D6 and 2C19 alleles that are associated with poor metabolizer status in the treatment-intolerant population will far exceed the rate found in patient population who takes antidepressants without adverse effects.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-12 |
What the finished NCT00360256 record still lists
NCT00360256 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00360256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00360256 about?
NCT00360256 is a clinical study titled "Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants". The objective of this pilot study is to determine the genetic polymorphism rate of CYP450 2D6 and 2C19 metabolic enzymes in patients with significant adverse effects from antidepressants, compared to a population of patients who had no significant adverse effects from antidepressants metabolized by ...
What is the current status of trial NCT00360256?
This trial is currently completed. The enrollment target is 46 participants. The study started on 2006-06. Estimated completion is 2007-12.
Who is sponsoring clinical trial NCT00360256?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia